{
  "id": 1933,
  "text": "1681</td><td>1999</td><td>20</td><td>Cisplatin/paclitaxel</td><td>45</td><td>7</td></tr><tr><td>Moore et al.1629</td><td>2004</td><td>130</td><td>Cisplatin/paclitaxel</td><td>35</td><td>9.7</td></tr><tr><td>Monk et al.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1681</td><td>1999</td><td>20</td><td>Cisplatin/paclitaxel</td><td>45</td><td>7</td></tr><tr><td>Moore et al.1629</td><td>2004</td><td>130</td><td>Cisplatin/paclitaxel</td><td>35</td><td>9.7</td></tr><tr><td>Monk et al.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "临床试验中，常用于治疗晚期宫颈癌的化疗方案包括顺铂联合紫杉醇（Cisplatin/paclitaxel）的治疗组合。根据研究，顺铂联合紫杉醇方案在晚期宫颈癌中的疗效数据如下：\n\n- 一项试验显示该方案的总缓解率为45%，中位生存时间为7个月。\n- 另一项试验报告总缓解率为35%，中位生存时间为9.7个月。\n\n这些数据表明，顺铂联合紫杉醇方案在提高总缓解率和延长患者生存期方面具有一定疗效，但中位生存时间较短，仍需进一步优化治疗选择及开展相关研究。",
  "query": "在临床试验中，有哪些化疗方案常用于治疗晚期宫颈癌？这些方案的疗效如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在临床试验中，有哪些化疗方案常用于治疗晚期宫颈癌？这些方案的疗效如何？\n\n<reference text>: 1681</td><td>1999</td><td>20</td><td>Cisplatin/paclitaxel</td><td>45</td><td>7</td></tr><tr><td>Moore et al.1629</td><td>2004</td><td>130</td><td>Cisplatin/paclitaxel</td><td>35</td><td>9.7</td></tr><tr><td>Monk et al.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "临床试验中，常用于治疗晚期宫颈癌的化疗方案包括顺铂联合紫杉醇（Cisplatin/paclitaxel）的治疗组合。根据研究，顺铂联合紫杉醇方案在晚期宫颈癌中的疗效数据如下：\n\n- 一项试验显示该方案的总缓解率为45%，中位生存时间为7个月。\n- 另一项试验报告总缓解率为35%，中位生存时间为9.7个月。\n\n这些数据表明，顺铂联合紫杉醇方案在提高总缓解率和延长患者生存期方面具有一定疗效，但中位生存时间较短，仍需进一步优化治疗选择及开展相关研究。"
}